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Abstract
The mammalian target of rapamycin (mTOR), an evolutionarily conserved serine/threonine protein kinase, integrates
both intracellular and extracellular signals and serves as a central regulator of cell metabolism, growth, proliferation,
survival, and autophagy. The mTOR pathway is frequently activated in many human cancers, mainly resulting from
alterations in the upstream regulators, such as phosphoinositide 3-kinase (PI3K)/AKT activation, PTEN loss or dys-
regulation of mTOR-negative regulators (e.g., TSC1/2), leading to uncontrolled proliferation. Thus, inhibiting the PI3K/
AKT/mTOR pathways is widely considered as an effective approach for targeted cancer therapy. Recently, we and
others found that DEPTOR, a naturally occurring inhibitor of both mTORC1 and mTORC2, was degraded by SCF
(Skp1-Cullin-F box proteins) E3 ubiquitin ligase, the foundingmember of cullin-RING-ligases (CRLs), resulting in mTOR
activation and cell proliferation. In addition to DEPTOR, previous studies have demonstrated that several other neg-
ative regulators of mTOR pathway are also substrates of CRL/SCF E3s. Thus, targeting CRL/SCF E3s is expected to
cause the accumulation of these mTOR signal inhibitors to effectively block the mTOR pathway. In this review, we
will discuss mTOR signaling pathway, how DEPTOR regulates mTOR/AKT axis, thus acting as a tumor suppressor or
oncogene in some cases, how DEPTOR is ubiquitinated and degraded by SCFβ-TrCP E3, and how MLN4924, a small-
molecule indirect inhibitor of CRL/SCF E3 ligases through blocking cullin neddylation, might be useful as a novel
approach of mTOR pathway targeting for cancer therapy.
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The mTOR and mTOR Signaling Pathway:
An Introduction
The mammalian target of rapamycin (mTOR), an evolutionarily
conserved serine/threonine protein kinase, integrates both intracellular
and extracellular signals and serves as a central regulator of cell metab-
olism, growth, proliferation, survival, and autophagy [1,2]. In mamma-
lian cells, mTOR forms two structurally and functionally distinct
complexes, namely mTORC1 andmTORC2 [3,4].Whereas mTORC1
consists of mTOR, Raptor, mLST8/GβL, PRAS40, and DEPTOR,
mTORC2 is composed of mTOR, Rictor, GβL, Protor, Sin1, and
DEPTOR [1,2]. It is well known that mTORC1mainly promotes pro-
tein translation and cell growth by phosphorylating S6K1 and 4E-BP1,
whereas mTORC2 regulates cytoskeletal organization [5] as well as cell
survival through directly phosphorylating and activating AKT [3,4].
In addition, as a negative feedback loop, mTORC1 through S6K
inhibits AKT by downregulating the expression of IRS-1/2 to block
phosphoinositide 3-kinase (PI3K) activation [3,4]. Furthermore, mTORs
are well-established negative regulators of autophagy [6,7]; whereas
mTORC1 inhibits autophagosome formation by phosphorylating
Ulk1/2 and Atg13 [8,9], mTORC2 represses the expression of some
autophagy-related genes and other autophagy regulators [10–13]. Like-
wise, rapamycin, a potent inhibitor of mTOR, is commonly used as an
autophagy inducer [6,14].
In response to multiple signals, including growth factors, nutrients,
energy, and stress, mTOR is activated or inactivated, resulting in altered
cellular processes [1,5,15]. On exposure to growth factors, mTOR is
activated through 1) the PI3K-AKT pathway, leading to inactivation
of TSC2, a negative regulator of mTOR [16], which complexes with
TSC1 to inactivate Rheb GTPase, anmTORC1 activator [16–18]; and
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2) the RAS-ERK-RSK pathway, which also phosphorylates and inhibits
TSC2 [19,20]. We recently showed that RSK1 could directly target the
mTOR complex by phosphorylating DEPTOR, an mTOR inhibitor
[21], thereby promoting its degradation [22] (see below). In response
to hypoxia, HIF-1 is induced to block mTORC1 through the HIF-1–
REDD1 axis, which activates the TSC1-TSC2 complex through less
well-defined mechanisms or a mechanism involving 14-3-3 [23,24].
Furthermore, TSC2 is activated by the cellular energy sensor AMP-
activated protein kinase (AMPK). When the ratio of AMP/ATP is
increased, AMPK is activated to phosphorylate and activate TSC2,
leading to mTORC1 inactivation [25]. AMPK also inhibits mTOR by
directly phosphorylating and inactivating Raptor in a TSC2-independent
manner [26]. By phosphorylating and activating AMPK, the tumor sup-
pressor LKB1 also significantly abrogates mTOR signaling [27]. Finally,
mTORC1 can be activated by amino acids through Rag GTPases
[28,29]. However, the upstream activators of mTORC2 are ill defined,
but it is generally thought that mTORC2 is activated directly or indi-
rectly only by growth factors [2]. Figure 1 briefly summarizes the
signaling pathways that respond to various stimuli, leading to mTOR
activation and subsequent cell growth and proliferation, survival, and
autophagy inhibition.
DEPTOR, an mTOR Inhibitor: A Tumor Suppressor
or an Oncogene?
Recently, Sabatini’s group discovered a novel mTOR binding partner,
designated as DEPTOR in reference to the presence of two tandem
N-terminal DEP (disheveled, egl-10, pleckstrin) domains with un-
known function [30] and its specific interaction with mTOR [21].
DEPTOR also contains a C-terminal PDZ (postsynaptic density 95,
discslarge, zonula occludens-1) domain [31], which is often involved
in protein-protein interaction. Indeed, DEPTOR binds to FAT domain
on mTOR through its PDZ domain [21]. Significantly, DEPTOR
binds to both mTORC1 and mTORC2 and inhibits their activities,
as measured by in vitro kinase assay as well as in cell-based assays.
Nevertheless, the messenger RNA (mRNA) and protein levels of
DEPTOR are negatively regulated by the activities of both mTORC1
and mTORC2, establishing a regulatory feedback loop [21].
By blocking the activity of mTOR, DEPTOR acts, in general, as
a tumor suppressor through inhibiting protein synthesis, cell prolif-
eration, and survival. Indeed, small interfering RNA knockdown of
DEPTOR increased the activities of both mTORC1 and mTORC2,
as evidenced by increased S6K1/AKT phosphorylation, and thereby
promoting cell proliferation and survival [1,21] (Figure 2A). However,
under certain circumstances, DEPTOR could act as an oncogene
[21,32]. High levels of DEPTOR inhibited mTORC1 and activated
AKT by relieving the feedback inhibition from S6K1 to PI3K, as dem-
onstrated by reduced S6K1 phosphorylation and increased AKT
phosphorylation, thus promoting the survival of cancer cells [21,22]
(Figure 2B). It is not surprising that the levels of DEPTOR are down-
regulated inmost cancers because themTORpathway negatively regulates
DEPTOR mRNA expression and protein stability [21]. In a subset
(∼28%) of human multiple myelomas, however, DEPTOR was overex-
pressed. In these cells, high levels of DEPTORwere required for the main-
tenance of PI3K/AKT activation and small interfering RNA knockdown
of DEPTOR induced apoptotic cell death [21]. Consistently, increased
DEPTOR rendered cancer cells more resistant to chemotherapeutic drugs
Figure 1. The mTOR signaling pathway. Arrows stand for activation; bars represent inhibition. represents phosphorylation. For de-
tails, see text.
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[22,33,34]. Finally, DEPTOR overexpression was found in hepatocellular
carcinoma and differentiated thyroid carcinoma, which correlated with the
poor prognosis of patients [35,36]. These conflicting data suggest a com-
plex role of DEPTOR in the regulation of mTOR signaling pathways as
well as other yet-to-be-identified pathways in a tissue-specific and cell
context–dependent manner. The in vivo physiological role of DEPTOR
as a tumor suppressor or oncogene will only be clearly demonstrated in
mouse knockout studies by determining the effect on tumorigenesis on
Deptor deletion (total or tissue specific) alone or in combination with,
for example, Ras activation or Pten loss.
DEPTORUbiquitination and Degradation by SCFβ-TrCP
E3 Ubiquitin Ligase
Although it was established that mTOR promotes DEPTOR degra-
dation on mitogen stimulation [21], the E3 ubiquitin ligase, respon-
sible for DEPTOR degradation, was unknown until most recently.
Three independent groups, including ours, identified SCFβ-TrCP E3
ubiquitin ligase is the E3 that promotes the ubiquitination and deg-
radation of DEPTOR in response to serum stimulation [22,33,37].
Cullin-RING ligases (CRLs) with the founding member, SCF E3,
are the largest E3 ubiquitin ligase family. CRLs seem to account for
∼20% of total protein degradation by the ubiquitin-proteasome system
[38]. By promoting ubiquitination and degradation of a variety of key
substrates, CLRs control a number of important biologic processes
including cell cycle progression, signal transduction, gene transcription,
embryonic development, genomic integrity, and tumor suppression
[39–41]. In mammalian cells, there are a total of eight members of
the cullin family of proteins (CUL1, 2, 3, 4A, 4B, 5, 7, and PARC)
[42], which individually binds to an adaptor protein (such as SKP1 and
DDB1) and a substrate receptor protein (such as F-box protein) at the
N-terminus, and a RING protein, RBX1 or RBX2 (also known as
ROC2 or SAG) at the C-terminus [43]. It is well established that the
substrate specificity of CRLs/SCF E3s is determined by substrate recep-
tor proteins, such as F-box proteins [44], whereas the core ligase activity
is possessed by the cullins-RBX1/2 complex [45].
Now how does SCFβ-TrCP promote DEPTOR ubiquitination and
degradation? It is well established that in order for F-box proteins to
bind to its substrates for subsequent ubiquitination and degradation, the
substrates have to be phosphorylated first at the serine or threonine
residue(s) on a consensus-binding motif of a given F-box protein [39].
In the case of DEPTOR, we did identify an evolutionarily conserved
consensus β-TrCP binding motif (DSGXXS) on residues 286 to 291
(SSGYFS ). The only mismatch here is the replacement of the con-
served aspartic acid (D) by a serine (S) (see Figure S1A in Zhao et al.
[22]), which, nevertheless, behaves as aspartic acid on phosphorylation.
The exact same sequence of the binding motif was identified on BimEL,
a previously characterized substrate of SCFβ-TrCP [46]. We further iden-
tified that kinases S6K1, a downstream target of mTORC1, and RSK1
are responsible for DEPTOR phosphorylation at the S286-S287-S291
residues, with S6K1 acting as a prime kinase, although which kinase
actually phosphorylates which serine residue remains to be defined
[22,47]. Conversely, two other groups reported that mTOR and
CK1α are the responsible kinases with mTOR acting as a prime kinase
to facilitate DEPTOR phosphorylation on three serine residues at the
binding motif (286SSGYFS291) by CK1α [33,37]. To further clarify
this discrepancy, we performed an in vitro kinase assay for DEPTOR
phosphorylation on these three serine residues (Ser286,287,291), using a
specific phosphor antibody raised against a peptide with all three serine
Figure 3. DEPTOR is ubiquitinated by SCFβ-TrCP E3 ligase on phosphorylation. (A) In vitro phosphorylation of DEPTOR on the consensus-
binding motif. FLAG-tagged DEPTOR was transfected into 293 cells, purified by IP using bead-conjugated anti-FLAG Ab, and incubated
with active CK1 or mTOR alone or in combination, as well as the combination of active S6K1 and RSK1 in a kinase reaction mixture.
DEPTOR phosphorylation on Ser286,287,291 was detected by immunoblotting using a DEPTOR phosphor-specific Ab [22]. (B) Schematic
summary of DEPTOR ubiquitination by SCFβ-TrCP E3 ubiquitin ligase and degradation by 26S proteasome. In response to mitogen, RSK1
and S6K1 are activated to phosphorylate DEPTOR at β-TrCP degron site [22]. Conversely, DEPTOR is phosphorylated by mTOR at non-
degron site, which acts as primer for subsequent phosphorylation at degron site by CK1α [33,37]. Phosphorylated DEPTOR is then recog-
nized by β-TrCP for subsequent ubiquitination by SCF E3 and degradation by proteasome.
Figure 2. DEPTOR has tumor suppressive and oncogenic proper-
ties. (A) DEPTOR acts as a tumor suppressor. (B) DEPTOR acts as an
oncogene. For details, see text.
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residues phosphorylated [22]. As shown in Figure 3A, immune-purified
FLAG-tagged DEPTOR was phosphorylated by mTOR (slightly) and
CK1α alone or in combination or by the combination of S6K1 and
RSK1. Thus, the combination of either mTOR/CK1α or S6K1/
RSK1 was able to phosphorylate this binding motif in vitro. The in vivo
DEPTOR phosphorylation for its targeted degradation, however, will
likely be triggered by a different set of kinases activated in response to a
given stimulus. Taken together, these combined results indicate that
mTOR positively regulates its own activity by inducing the ubiquitination
and degradation of DEPTOR, one of its own endogenous inhibitors,
either directly or through its downstream target S6K1 [22,33,37,47].
On phosphorylation on β-TrCP binding motif, DEPTOR is bound to
β-TrCP, which recruits E2-loaded RBX1-Cullin 1 complex, catalyzing
ubiquitin transfer from E2 to DEPTOR. Multiple runs of this E1/E2/
E3–mediated chain reaction cause DEPTOR polyubiquitination,
which is then recognized by the 26S proteasome for subsequent degra-
dation (Figure 3B) [22,33,37].
CRLs/SCF E3 Ligases Degrade Multiple Components
of mTOR Pathway
In addition to DEPTOR, a variety of components, both upstream
and downstream, of mTOR signaling pathway were found to be the
substrates of CRLs/SCF E3 ligases (Figure 4A). First of all, mTOR
itself was reported to undergo ubiquitin-mediated degradation by
Cul1-Skp1-Fbw7 E3 ligase, although the kinase(s) responsible for pre-
requisite phosphorylation was not defined [48]. Second, TSC2 was
identified as the substrate of Cul4-DDB1-Fbw5 E3 ligase that medi-
ated TSC2 protein stability and TSC complex turnover [49]. Third,
REDD1 was rapidly degraded by Cul4A-DDB1-β-TrCP E3 ligase with
GSK-3β as a corresponding kinase for prerequisite phosphorylation
[50]. Fourth, HIF-1α was a well-characterized substrate of Cul2-
Elongin BC-VHL E3 ligase [51,52]. Fifth, IRS1 can be ubiquitinated
and degraded either by Cul7-Skp1-Fbw8 in a manner dependent of
mTOR and S6K [53] or by Cul1-Skp1-Fbxo40 E3 ligase with ligase
activity enhanced by increased tyrosine phosphorylation of IRS1 [54].
Figure 4. CRLs/SCF E3 ubiquitin ligases regulate mTOR pathway. (A) Schematic summary of CRLs/SCF E3 substrates in mTOR signaling
pathway. (B) Schematic summary of cullin neddylation. (C) Schematic summary of ubiquitination reaction catalyzed by SCF E3 ubiquitin
ligases and potential targeting points for inhibition. For details, see text.
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Sixth, PHLPP1, a protein phosphatase that dephosphorylates acti-
vated AKT, was found to be substrate of SCFβ-TrCP on phosphorylation
by CK1 and GSK-3β [55]. Finally, PDCD4, a downstream target of
mTOR/S6K1, was identified as a substrate of Cul1-Skp1-β-TrCP E3
ligase on prerequisite phosphorylation at Ser67 by S6K1 [56]. Thus,
given the fact that all these CRLs E3 substrates, except mTOR itself
and IRS1, are the negative regulators of mTOR pathway, the small-
molecule inhibitor of CRLs/SCF E3 ligases would likely cause the
accumulation of these negative regulators to shut down mTOR path-
ways, leading to suppression of cell proliferation and survival.
Targeting mTOR Pathway by Inactivating CRL/SCF
E3s: Therapeutic Application
The mTOR pathway is frequently and constitutively activated in
many types of human cancer mainly through activation of PI3K/
AKT and inactivation of PTEN in the upstream signaling pathways
[3,5,57,58]. The PI3K/AKT signaling is activated through a variety of
mechanisms, including mutations or amplifications of cell surface
receptor tyrosine kinases (RTKs), such as EGFR [59–61] and IGFR
[62,63], the gain-of-function mutations in the PIK3CA gene itself,
which encodes the p110a catalytic subunit of PI3K [64–66], and loss
of expression of the tumor suppressor PTEN, which encodes a lipid
and protein phosphatase [67]. PTEN inactivation is found in many
cancers, such as carcinomas of breast, endometrium, thyroid, and
prostate as well as melanoma, leukemia, lymphoma, and glioblastoma,
through several mechanisms, including mutations, deletions, loss of
heterozygosity, methylation, and microRNA silencing [67]. Further-
more, mTOR activation was also found in several benign tumor syn-
dromes, including tuberous sclerosis (TSC1/2 mutations) [25],
Peutz-Jeghers syndrome (LKB1 mutations) [27], Cowden syndrome
(PTEN mutations) [68], and neurofibromatosis (NF1 mutations)
[69]. Thus, PI3K/AKT/mTOR pathways are considered as attractive
targets for effective cancer treatment [64,70–74].
Given the association of mTOR with a wide variety of diseases
including cancer, metabolic disorders, neurologic diseases, and auto-
immune diseases [2], mTOR inhibitors may therefore have a broad
application in the treatment of these diseases. Rapamycin (sirolimus) and
its analogs (rapalogs), which include temsirolimus (CCI-779) [75],
everoliums (RAD001) [76], and deforolimus (AP23573) [77], are
the first generation of mTOR inhibitors [73], which form a complex
with the immunophilin FKBP12 and inhibit mTORC1 activity
through binding to FRB (FKBP12-rapamycin-binding) domain on
mTOR [78]. Numerous clinical trials are ongoing to test their efficacy
as anticancer agents, but with limited success [73,79,80]. The cancer
resistance to rapamycin type of drugs could be attributable to the exis-
tence of the negative feedback mechanism by which inactivation of
mTORC1/S6K1 releases S6K1 inhibition on IRS-PI3K, leading to
activation of AKT for cancer cell survival [73]. Thus, inhibition of
mTORC1 reduces cell growth but could improve the survival [81]. Re-
cently, ATP-competitive inhibitors, such as Torin1 [82], PP242 and
PP30 [83], which directly target the catalytic site of mTOR kinase
and inhibit both mTORC1 and mTORC2 kinase activity, were devel-
oped as the second generation of mTOR inhibitors, currently in early
stage of clinical trials with a better anticancer efficacy than rapalogs in
preclinical settings [80,84].
An alternative approach of blocking mTOR or mTOR pathway,
which has never been tested before, would be through modulating
the stability of mTOR-negative regulators. Given the fact that most
mTOR signal blockers, such as DEPTOR, HIF-1α, REDD1, TSC2,
and PDCD4, are substrates of CRLs/SCF E3 ligases, small-molecule
inhibitors of the CRL/SCF E3s are expected to cause their accumula-
tion, thus abrogating mTOR pathway, particularly in human cancers
with constitutive mTOR activation. Unfortunately, specific small-
molecule inhibitor against the multicomponent CRL/SCF E3 ligases
has not been discovered to test this hypothesis. However, MLN4924,
a newly discovered small-molecule inhibitor of NEDD8-activating
Enzyme (NAE) [38], could act as an indirect inhibitor of CRL/SCF
E3s, thus to be used as an alternative option.
Like ubiquitination, neddylation requires E1 NEDD8-activating
enzyme, E2 NEDD8-conjugating enzyme (UBC12), and E3 NEDD8
ligase to catalyze the transfer of NEDD8 to a target molecule [85,86]
(Figure 4B). Inhibition of either enzyme in the reaction would abrogate
substrate neddylation. MLN4924 is a newly discovered small-molecule
inhibitor of NAE [38]. MLN4924 binds to NAE to create a covalent
NEDD8-MLN4924 adduct, which cannot be further used in sub-
sequent intraenzyme reactions, thus blocking NAE enzymatic activity
[87] (Figure 4B). Because the activity of CRL/SCF E3s requires cullins
neddylation, which disrupts inhibitory binding by CAND1 and retains
the CRLs/SCFs in an active conformation [88–91], MLN4924 became
the first-in-class indirect inhibitor of CRL/SCF E3s [38]. By inactivat-
ing CRL/SCF E3s, MLN4924 causes the accumulation of a number of
SCF E3 substrates to inducing apoptosis [38,92–95] and senescence
[96–98], thus inhibiting tumor growth both in vitro and in vivo. We
used MLN4924 as an alternative mTOR pathway inhibitor and found
that it effectively blocked the activity of mTORC1 in both time- and
dose-dependent manners in almost all tested human cancer cell lines
derived from carcinomas of breast, prostate, colon, brain, and cervix
(unpublished observations). Thus, antitumor activity of MLN4924
could be attributable to its inhibition of the mTOR pathway. It is
worth noting that among these reported substrates of CRL/SCF E3s
in the mTOR pathway, HIF-1α, DEPTOR, and PDCD4 were most
frequently accumulated, whereas mTOR itself, TSC2, and REDD1
were never accumulated on MLN4924 treatment in all tested cell lines
under our assay conditions (unpublished observations). The differential
MLN4924 responses, in substrate accumulation among tested cancer
lines, are likely attributable to cell line– and cell context–dependent
availability of F-box/adaptor proteins as well as of kinases prerequisite
for substrate phosphorylation.
It should be clearly noted that, although MLN4924 demonstrated
a universal inhibitory activity against mTORC1, it suffers from a
major specificity issue as an mTOR pathway blocker. First of all, there
are thousands of CRL/SCF substrates, given the fact that CRLs can be
assembled into more than 200 different E3 enzymes by different com-
binations of its multiple components [39,99]. Apparently, some of the
substrates are oncogenes, whereas others are tumor suppressors
[40,100]. The net biologic outcome of MLN4924 action (such as
induction of apoptosis, senescence, or even autophagy; unpublished
observation) would likely depend on the interaction of these substrates
in a cell context–, temporal-, and spatial-dependent manner. Second,
MLN4924 is an NAE inhibitor and would likely inhibit other cellular
neddylation reactions (much to be learned) [85,86], although cullins
are the only physiological substrates [85,101]. Third, it has been recent-
ly reported that cancer cells could develop the resistance to MLN4924
by selection of rare clones with heterozygous mutations in targeting
enzyme NAEβ [102,103]. Nevertheless, MLN4924 is the first-in-class
and only indirect inhibitor of SCF E3 ligases, which demonstrated
potent anticancer activity with limited toxicity in mice in preclinical
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settings [38,104] and has been advanced to several phase 1 clinical
trials [105,106].
Future Perspectives on DEPTOR Biology and
CLR/SCF E3 Inhibitors
Although activation of PI3K-AKT-mTOR pathway, resulting from
PI3K/AKT mutation and/or PTEN loss, plays a key role in pro-
moting cell proliferation/survival and tumorigenesis in many human
cancers [64,67,70,107], it is totally unknown how this oncogenic
pathway is regulated by DEPTOR under in vivo physiological settings,
particularly given the fact that DEPTOR could act as a tumor sup-
pressor or oncogene in cell culture settings [1,21]. Several DEPTOR
biologic questions remain to be addressed: 1) Is Deptor a tumor sup-
pressor or an oncogene in vivo when acting alone? 2) Can Deptor affect
tumorigenesis triggered by activation of PI3K-AKT-mTOR axis as a
result of Ras activation or Pten loss? 3) Can targeting DEPTOR degra-
dation suppress tumorigenesis in vivo? The answers to these funda-
mental questions by the use of genetically modified mouse models
and human tumor xenograft models would certainly further our current
understanding of DEPTOR function and its regulation of PI3K-AKT-
mTOR axis, and provide molecular basis for rational drug design in
targeting this oncogenic axis.
With regard to specific inhibitors of CRL/SCF E3s, which have
been validated as the attractive anticancer targets [108,109], encour-
aging progresses are being made. Examples include the discovery of
Cpd A that disrupted Skp2-p27 binding to abrogate p27 degradation
[110] and discovery of few SCF-Cdc4 inhibitors [111,112] and a
Cdc34 inhibitor [113]. Other options include 1) disruption of E2
binding with RING proteins, RBX1/RBX2; 2) disruption of receptor
binding with tumor suppressive substrates; and 3) inhibition of kinases
that phosphorylate tumor suppressor substrates for targeted deg-
radation (Figure 4C ). It is hoped that specific inhibitors targeting
CRL/SCF E3s will be eventually discovered and further developed as
novel anticancer agents for the treatment of human cancers with acti-
vated CRL/SCF E3s.
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